We then aimed to determine whether AAV9-based gene delivery that effectively prevented arrhythmias in genetically-modified mice (R33Q-CASQ2 knock-in and CASQ2 knockout)5, 6 is also effective in patient-derived myocytes. The gene discussed is CASQ2; the disease is Arrhythmia.